Security key
09075P105
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI)
CUSIP: 09075P105
Q1 2023 13F Holders as of 31 Mar 2023
- Security type / class
- Equity / Common Stock, par value $0.001
- Total 13F shares
- 17,417,079
- Total 13F value
- $324,965,795
- Share change
- +3,894,966
- Put/Call ratio
- 67%
- SEC-reported price per share
- $18.66
- Number of holders
- 96
- Value change
- +$71,330,482
- Number of buys
- 51
- Number of sells
- 38
- Shares outstanding
- 27,093,277
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2023
Institutions
96
Top holders
10
BTAI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
BioXcel Therapeutics, Inc. SEC filings
BioXcel Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09075P105
Recent filing periods:
Ownership snapshot
Top reported holders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Dec 2022
13F
Lead comparable stake: 16%
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 16%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
16%
BlackRock Finance, Inc.
5.4%
Artemis Investment Management LLP
4.9%
VANGUARD GROUP INC
3.9%
ADAGE CAPITAL PARTNERS GP, L.L.C.
3.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
Company
|
16%
|
$90,289,806
4,203,436 shares
|
— | 31 Dec 2022 |
| BlackRock Finance, Inc. |
13F
Company
|
5.4%
|
$31,423,564
1,462,922 shares
|
— | 31 Dec 2022 |
| Artemis Investment Management LLP |
13F
Company
|
4.9%
|
$28,748,877
1,333,691 shares
|
— | 31 Dec 2022 |
| VANGUARD GROUP INC |
13F
Company
|
3.9%
|
$22,429,501
1,044,204 shares
|
— | 31 Dec 2022 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
3.2%
|
$18,795,000
875,000 shares
|
— | 31 Dec 2022 |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
Company
|
1.9%
|
$10,867,462
505,934 shares
|
— | 31 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
96
Shares
17,417,079
Rows available
96
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2023 vs Q3 2025 Across Filers
Q3 2025 holders
1
Q1 2023 holders
96
Holder diff
95
| Investor | Q3 2025 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q3 2025 value | Q1 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend